- In December 2024, AngioDynamics Inc. achieved a significant milestone by receiving FDA clearance for their NanoKnife System for prostate tissue ablation. This clearance followed the completion of the pivotal PRESERVE clinical study, which evaluated the safety and effectiveness of the system for ablating prostate tissue in patients with intermediate-risk prostate cancer. The study demonstrated strong quality of life outcomes, with a high percentage of men remaining free from in-field, clinically significant disease at 12 months post-procedure. This development is expected to accelerate the adoption of the NanoKnife System and redefine the standard of care for prostate health
- In November 2024, Boston Scientific announced that it had entered into a definitive agreement to acquire Intera Oncology Inc., a privately held medical device company. Intera Oncology provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine, a chemotherapy drug, both of which are approved by the U.S. Food and Drug Administration. The Intera 3000 pump is used to administer hepatic artery infusion (HAI) therapy to treat tumors in the liver, primarily caused by metastatic colorectal cancer
- In September 2024, Varian, a Siemens Healthineers company, announced a 10-year agreement with Ballad Health to bring advanced oncology treatment services to patients in rural communities across the Appalachian Highlands in Northeast Tennessee, Southwest Virginia, northwestern North Carolina, and southeastern Kentucky. This transformational oncology collaboration aims to deliver advanced treatment technology through a highly integrated digital network, accelerating the patient journey from screening to survivorship. The agreement includes a portfolio of products and services supporting a unified oncology ecosystem, such as Varian’s ARIA CORE oncology management solution and the Varian Executive Partnership program
- In November 2023, ProSense received regulatory approval in India from the Central Drugs Standard Control Organisation (CDSCO) based on updated regulatory requirements. This approval allows ProSense to be marketed and sold in India, enhancing its presence in the market. The ProSense system, developed by IceCure Medical, is a minimally invasive cryoablation technology that destroys tumors by freezing, offering an alternative to surgical tumor removal. This approval is expected to drive the adoption of ProSense in India, particularly for breast cancer cryoablation procedures
- In May 2023, Varian, a Siemens Healthineers company, introduced the Isolis™ cryoprobe, a single-use, disposable device designed for use with CryoCare® systems to improve procedural efficiency and precision for cryoablation. The Isolis cryoprobe offers interventional radiologists greater control, precision, and efficiency during cryoablation procedures. It features a small 2.1mm/14-gauge shaft and a sharp probe tip for smooth and accurate placement. In addition, it is the first cryoprobe to offer optional integration with the Siemens Healthineers myNeedle Laser guidance system, enhancing predictability and precision during image-guided interventional procedures
Frequently Asked Questions
The primary challenges include high procedural costs limit access to interventional oncology and shortage of skilled professionals hinders.
Embolization devices are the dominating segment in the interventional oncology market. This segment includes products such as drug-eluting beads, microspheres, and radioembolization devices, which are used to block the blood supply to tumors, causing them to shrink. The high demand for these devices is driven by their effectiveness in treating various types of cancer, including liver, kidney, and lung cancers.
